Research Story Tip: Grants, Management Roles Keep Johns Hopkins A Leader In Hiv/Aids Clinical Trial

Date: 12/08/2020

Publication:

hopkinsmedicine.org

This World AIDS Day, HIV/AIDS researchers at Johns Hopkins Medicine learned that they now have an enhanced opportunity to help move the world toward a day when that observance is rendered obsolete. The National Institutes of Health (NIH)’s National Institute of Allergy and Infectious Diseases (NIAID) announced Dec. 1, 2020, that Johns Hopkins Medicine will receive five of the seven-year grants awarded to 35 U.S. and international institutions to operate clinical trial units (CTUs) and coordinate HIV/AIDS clinical trials in four federally funded networks.

The three CTU grants and two leadership awards for Johns Hopkins Medicine are the most given to any one institution.

Full Article Here

Clinical Trials

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More